These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31776044)

  • 21. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
    Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A
    N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
    Tirani M; Meregaglia M; Melegaro A
    PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
    Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
    JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meningococcal Serogroup B Disease in Vaccinated Children.
    Soler-Garcia A; Fernández de Sevilla M; Abad R; Esteva C; Alsina L; Vázquez J; Muñoz-Almagro C; Noguera-Julian A
    J Pediatric Infect Dis Soc; 2020 Sep; 9(4):454-459. PubMed ID: 31634404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
    Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
    J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.
    Lodi L; Barbati F; Amicizia D; Baldo V; Barbui AM; Bondi A; Costantino C; Da Dalt L; Ferrara L; Fortunato F; Guarnieri V; Icardi G; Indolfi G; Martinelli D; Martini M; Moriondo M; Nieddu F; Peroni DG; Prato R; Ricci S; Russo F; Tirelli F; Vitale F; Ladhani SN; Azzari C;
    JAMA Netw Open; 2023 Aug; 6(8):e2329678. PubMed ID: 37594762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.